Raymond J. Furey serves as the Executive Vice President, General Counsel, Chief Compliance Officer, and Corporate Secretary at Rigel Pharmaceuticals, Inc., a biotechnology company focused on developing novel therapies for hematologic disorders and cancer. In his multifaceted role, Furey is responsible for overseeing the company's legal affairs, ensuring compliance with regulatory standards, and managing corporate governance. His leadership is pivotal in navigating the complex legal landscape of the pharmaceutical industry, ensuring that Rigel Pharmaceuticals operates within the bounds of the law while pursuing its mission to bring innovative treatments to patients. Before joining Rigel Pharmaceuticals, Furey had an extensive career in the legal field, with a strong background in corporate law and compliance. He previously served as Senior Vice President, General Counsel, and Corporate Secretary at Medivation, Inc., where he played a key role in the company's growth and eventual acquisition by Pfizer. His experience also includes time at Chiron Corporation, where he held the position of Vice President, Associate General Counsel, and Assistant Secretary. Furey's expertise in mergers and acquisitions, intellectual property, and corporate governance has been instrumental in his success and has earned him a reputation as a strategic thinker and effective leader in the biotechnology sector. Furey's contributions to Rigel Pharmaceuticals extend beyond his legal and compliance duties. He is a member of the company's executive team, contributing to strategic decision-making and helping to steer the company's direction. His commitment to ethical practices and his ability to foster a culture of compliance have been crucial in maintaining Rigel's reputation as a responsible and innovative player in the biopharmaceutical industry. With his comprehensive understanding of the legal and regulatory challenges facing the sector, Furey continues to be a vital asset to Rigel Pharmaceuticals as it advances its pipeline of groundbreaking therapies.